Hannah Thomasy, PhD, Drug Discovery News | Jul 14, 2022 | 5 min read
University of Wollongong epidemiologist Gideon Meyerowitz-Katz speaks with The Scientist about his team’s finding that flawed and fraudulent COVID-19 research continues to be cited.
After a week of deliberation, a jury returned a guilty verdict on four charges related to wire fraud, each of which carries a maximum sentence of up to 20 years in prison.
Illinois-based Surgisphere Corporation had a brief moment in the limelight this year following its infamous study of hydroxychloroquine. But the impact of the company’s deception reverberated across world.
The high-profile retractions of two COVID-19 studies stunned the scientific community earlier this year and prompted calls for reviews of how science is conducted, published, and acted upon. The warning signs had been there all along.
BethAnn McLaughlin will step away from the organization after confirming allegations that she posed as @Sciencing_Bi, a fabricated queer indigenous researcher and victim of sexual harassment.
The company behind a now-discredited study on hydroxychloroquine also posted a report that has been cited by Latin American governments recommending ivermectin as a possible coronavirus treatment. Clinicians there say the effects have been extremely damaging.
A second investigation by the school concludes that David Latchman, also the head of Birkbeck, University of London, was not involved in the image manipulation found in papers he coauthored.